FDA Modernization Act of 1997
CBER FDAMA Guidances / Rules / Notices

Because CBER also regulates a number of medical devices, reference is made to the CDRH Guidance pertaining to FDAMA

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®.


Guidance for Industry: Reports on the Status of Postmarketing Study Commitments - Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 - 2/15/2006

Guidance for Industry: Fast Track Drug Development Programs - Designation, Development, and Application Review - 1/11/2006
    Appendix 2 (PDF)
    Appendix 3 - CDER MAPP 6020.3 (PDF), CBER SOPP 8405
    Appendix 4 (PDF)

Guidance for Industry: Developing Medical Imaging Drug and Biological Products - 6/17/2004

  • Part 1: Conducting Safety Assessments - (PDF)
  • Part 2: Clinical Indications - (PDF)
  • Part 3: Design, Analysis, and Interpretation of Clinical Studies - (PDF)

Draft Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions (Revision 1) - 1/26/2004 - (PDF), (Text)

FEDERAL REGISTER Mercury Compounds in Drugs and Food; List - 8/1/2003 - (PDF), (Text)

The Least Burdensome Provisions of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for FDA and Industry - 10/3/2002 - (PDF), (Text)

Guidance for Industry: Submitting and Reviewing Complete Responses to Clinical Holds - 10/26/2000
(PDF), (Text)

Guidance for Industry and FDA Staff: Guidance on Amended Procedures for Advisory Panel Meetings - 7/22/2000

Guidance for Industry: Formal Meetings With Sponsors and Applicants for PDUFA Products- 3/7/2000 - (PDF)

Guidance for Industry: Formal Dispute Resolution: Appeals Above the Division Level - 3/7/2000 - (PDF)

FEDERAL REGISTER Postmarketing Studies for Human Drugs and Licensed Biological Products; Status Reports; Proposed Rule - 12/1/99 - (PDF), (Text)

FEDERAL REGISTER Mercury Compounds in Drugs and Food; List and Analysis; Availability - 11/22/1999 - (PDF), (Text)

Guidance for Industry: Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug and Cosmetic Act - 10/8/1999 - (PDF), (Text)

FEDERAL REGISTER Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring - 5/17/99
(PDF), (Text)

Federal Register Notice: List of Documents Issued by the Food and Drug Adminstration That Apply to Medical Devices Regulated by CBER - 4/26/99 - (PDF), (Text)
      Refer to CDRH Guidance pertaining to FDAMA

Guidance for Industry: FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products - 2/3/99 - (PDF)

Draft Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products - (12 pages) - 11/30/98 - (PDF)

FEDERAL REGISTER FDA Plan for Statutory Compliance - 11/24/1998 - (PDF), (Text)
        Correction to plan - Federal Register Notice 12/17/1998 - (PDF), (Text)

Guidance for Industry; Advisory Committees: Implementing Section 120 of the Food and Drug Administration Modernization Act of 1997 - 10/30/98
    Federal Register Notice: (PDF), (Text)
    Guidance document: (PDF)

Federal Register: Food and Drug Administration Modernization Act of 1997; Allergenic Patch Test Kits; Request for Comments or Data - 10/1/98
(PDF), (Text)

Guidance for Industry: Implementation of Section 126, Elimination of Certain Labeling Requirements of the Food and Drug Administration Modernization Act of 1997 - 7/21/98
(PDF)

FEDERAL REGISTER - Dissemination of Information on Unapproved/New Uses for Marketed Drugs, Biologics and Devices; Proposed Rule - 6/8/98
(PDF), (Text)

FEDERAL REGISTER Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring; Proposed Rule - 5/22/98
(PDF), (Text)

List of Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population - 5/20/1998 - (PDF), (Text)

Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products - 5/15/98
(PDF)

Guidance for Industry: Standards for the Prompt Review of Efficacy Supplements, Including Priority Efficacy Supplements - 5/15/98
(PDF)

Guidance for Industry: Classifying Resubmissions in Response to Action Letters - 5/14/98
(PDF)

 
Updated: July 7, 2008